Two scientists in a lab testing samples.

A legacy of blood cancer innovation

Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.

The burden of IgAN

IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.

Shanelle Gabriel spending time with her father in New York

Novartis in Society Integrated Report 2023

Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.